- Home
- DERM
as 05-30-2025 4:00pm EST
Journey Medical Corp is a commercial stage pharmaceutical company focused on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions. The company's current product portfolio includes eight FDA-approved prescription drugs for dermatological conditions that are marketed in the U.S. Some of the group's products are Qbrexza, Accutane, Amzeeq, Exelderm and others.
| Founded: | 2014 | Country: | United States |
| Employees: | N/A | City: | SCOTTSDALE |
| Market Cap: | 181.0M | IPO Year: | 2021 |
| Target Price: | $10.00 | AVG Volume (30 days): | 103.3K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.39 | EPS Growth: | N/A |
| 52 Week Low/High: | $3.54 - $8.24 | Next Earning Date: | 05-14-2025 |
| Revenue: | $56,243,000 | Revenue Growth: | -29.69% |
| Revenue Growth (this year): | 29.83% | Revenue Growth (next year): | 54.88% |
Stock Insider Trading Activity of Journey Medical Corporation (DERM)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Maraoui Claude | DERM | President & CEO | May 2 '25 | Sell | $6.84 | 4,834 | $33,064.56 | 2,348,313 | |
| Benesch Joseph | DERM | CFO | May 2 '25 | Sell | $6.84 | 2,409 | $16,477.56 | 203,557 | |
| Alloush Ramsey | DERM | COO | May 2 '25 | Sell | $6.84 | 2,857 | $19,541.88 | 504,817 | |
| Maraoui Claude | DERM | President & CEO | Mar 11 '25 | Sell | $5.01 | 49,271 | $246,847.71 | 2,348,313 | |
| Maraoui Claude | DERM | President & CEO | Mar 6 '25 | Sell | $5.03 | 40,456 | $203,451.09 | 2,348,313 | |
| Maraoui Claude | DERM | President & CEO | Mar 3 '25 | Sell | $5.12 | 70,556 | $360,761.67 | 2,348,313 |
Latest Journey Medical Corporation News
DERM Breaking Stock News: Dive into DERM Ticker-Specific Updates for Smart Investing
GuruFocus.com
16 days ago
Journey Medical Corp (DERM) Q1 2025 Earnings Call Highlights: Amrosi Launch Boosts Margins ...
GlobeNewswire
16 days ago
Fortress Biotech Reports First Quarter 2025 Financial Results and Recent Corporate Highlights
Zacks
17 days ago
Journey Medical Corporation (DERM) Reports Q1 Loss, Tops Revenue Estimates
GlobeNewswire
17 days ago
Journey Medical Corporation Reports First Quarter 2025 Financial Results and Recent Corporate Highlights
GuruFocus.com
18 days ago
What To Expect From Journey Medical Corp (DERM) Q1 2025 Earnings
Zacks
23 days ago
The Joint Corp. (JYNT) Reports Q1 Loss, Tops Revenue Estimates
GlobeNewswire
24 days ago
Journey Medical Corporation to Announce First Quarter 2025 Financial Results on May 14, 2025
Zacks
a month ago
Strength Seen in Profound Medical (PROF): Can Its 8.3% Jump Turn into More Strength?
Compare DERM vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "DERM Journey Medical Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.